A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation

BACKGROUND: Long-term treatment with immunosuppressants is necessary to attenuate allograft rejection following organ transplantation (OT). Consequently, the overall survival of OT recipients with malignancies has been substantially compromised by tumour recurrence. Rapamycin (RAPA) is a clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhentao, Xie, Haiyang, Wan, Jianqin, Wang, Yuchen, Zhang, Liang, Zhou, Ke, Tang, Hong, Zhao, Wentao, Wang, Hangxiang, Song, Penghong, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196344/
https://www.ncbi.nlm.nih.gov/pubmed/37167784
http://dx.doi.org/10.1016/j.ebiom.2023.104594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196344/
https://www.ncbi.nlm.nih.gov/pubmed/37167784
http://dx.doi.org/10.1016/j.ebiom.2023.104594

Ejemplares similares